Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON-RT: SRS + Osimertinib vs Osimertinib Alone in NSCLC with Brain Metastases
NCT06741085Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Intracranial Progression-Free Survival at 3 months. Started Dec 2024; status: recruiting.
Beyond the preview
Go deeper on NCT06741085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741085.